| scholarly article | Q13442814 |
| P50 | author | Bernard Roizman | Q4893595 |
| P2093 | author name string | G Yancey Gillespie | |
| Bernard Perbal | |||
| Bin He | |||
| Richard J Whitley | |||
| James M Markert | |||
| Jacqueline N Parker | |||
| Catherine P Langford | |||
| Elizabeth K Hellums | |||
| Suman Bharara | |||
| P2860 | cites work | The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells | Q24523691 |
| Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis | Q33675567 | ||
| Genetically engineered HSV in the treatment of glioma: a review | Q33827571 | ||
| Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 | ||
| Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 | ||
| Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins | Q34463480 | ||
| Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma | Q34616722 | ||
| Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors | Q35051285 | ||
| Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells | Q35131235 | ||
| Expression of a herpes simplex virus 1 open reading frame antisense to the gamma(1)34.5 gene and transcribed by an RNA 3' coterminal with the unspliced latency-associated transcript. | Q36635409 | ||
| The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors | Q37247954 | ||
| Resistance to Herpes Simplex Virus — Type 1 (HSV-1) | Q40101865 | ||
| MICA/NKG2D-mediated immunogene therapy of experimental gliomas. | Q40604072 | ||
| Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model | Q41027561 | ||
| Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas | Q41054436 | ||
| A Clone of the MOCH-1 Glial Tumor in Culture: Multiple Phenotypes Expressed Under Different Environmental Conditions | Q41276897 | ||
| Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir | Q41563446 | ||
| Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression | Q41966417 | ||
| Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response | Q45624520 | ||
| Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 | ||
| Structural analysis of the human nov proto-oncogene and expression in Wilms tumor | Q48079794 | ||
| A syngeneic mouse glioma model for study of glioblastoma therapy | Q48284967 | ||
| Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells. Despite the presence of inducing signals GM-CSF is not expressed in vivo | Q48480817 | ||
| Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. | Q48727800 | ||
| Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. | Q55475423 | ||
| Human glioma immunobiology in vitro: implications for immunogene therapy. | Q55475673 | ||
| Cytokine gene expression on glioma cell lines and specimens. | Q55482455 | ||
| Granulocyte-macrophage colony-stimulating factor mRNA stabilization enhances transgenic expression in normal cells and tissues | Q72047270 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 213-224 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Neuro-Oncology | Q15724471 |
| P1476 | title | Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model | |
| P478 | volume | 7 |
| Q43189897 | "Armed" oncolytic herpes simplex viruses for brain tumor therapy |
| Q38714321 | A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells |
| Q56348401 | A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors |
| Q96685704 | Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas |
| Q39391503 | Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model |
| Q54248936 | Armed oncolytic viruses: A kick-start for anti-tumor immunity. |
| Q30395978 | Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus. |
| Q45323639 | Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory |
| Q36879211 | Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. |
| Q36849213 | Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. |
| Q34662536 | Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation |
| Q34318157 | Current status of gene therapy for brain tumors. |
| Q35559877 | Design and application of oncolytic HSV vectors for glioblastoma therapy |
| Q37064326 | Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma |
| Q38747475 | Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma |
| Q45354666 | Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice. |
| Q45411954 | Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors |
| Q58734384 | Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression |
| Q40146542 | Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses |
| Q91521080 | Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model |
| Q50525641 | Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery. |
| Q42234691 | Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates |
| Q33720628 | Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates |
| Q37031918 | Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy |
| Q40060078 | Gene Delivery in Neuro-Oncology |
| Q57006162 | Gene therapy and targeted toxins for glioma |
| Q35673628 | Gene therapy for malignant glioma |
| Q56378150 | HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses |
| Q35625666 | High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. |
| Q35126723 | Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells |
| Q36061803 | Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures. |
| Q30355682 | IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. |
| Q33574853 | Immunocompetent murine models for the study of glioblastoma immunotherapy |
| Q45863017 | Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma |
| Q39480423 | Involvement of TNFα-induced TLR4-NF-κB and TLR4-HIF-1α feed-forward loops in the regulation of inflammatory responses in glioma. |
| Q36890816 | NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors |
| Q89682703 | Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy |
| Q59793764 | Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins |
| Q26998111 | Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy |
| Q36634430 | Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice |
| Q36644898 | Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy |
| Q37492540 | Pharmacologic and chemical adjuvants in tumor virotherapy |
| Q42103783 | Posttranscriptional control of type I interferon genes by KSRP in the innate immune response against viral infection |
| Q35943736 | Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12 |
| Q27329466 | Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors |
| Q36546412 | Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases |
| Q37078999 | Prioritization schema for immunotherapy clinical trials in glioblastoma |
| Q35060701 | Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1 |
| Q34770256 | Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon. |
| Q37882608 | Rethinking herpes simplex virus: the way to oncolytic agents |
| Q35023693 | Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors |
| Q37818121 | Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents |
| Q37420576 | Strategies in gene therapy for glioblastoma. |
| Q37031664 | Viral therapy of glioblastoma multiforme |
Search more.